Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06607900 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

hUC-MSC-sEV-001 Nasal Drops for Neurodegenerative Diseases

StatusNot Yet Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Nov 1, 2024 to Jul 1, 2025v3 Show 4 more changesShow less
    • Primary endpoints: 5 to 6
    • Enrollment target: 100 to 120
    • Eligibility criteria expanded, about 289 words
    • Secondary endpoints: 12 to 17
  2. Re-verified, no change to tracked fieldsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Xuanwu Hospital, Beijing
204 trials monitored
See 3 trials at risk
Dementia
1,978 trials monitored
See 106 trials at risk
Parkinson's Disease
1,459 trials monitored
See 68 trials at risk
Alzheimer's Disease
1,253 trials monitored
See 71 trials at risk
and 1 more disease
To evaluate the safety and preliminary efficacy of human umbilical cord mesenchymal stem cell-derived small extracellular vesicles hUC-MSC-sEV-001 nasal drops in multiple neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, multiple system atrophy, Lewy body dementia, frontotemporal dementia, and amyotrophic lateral sclerosis.
Trial Details
NCT Number NCT06607900
Lead Sponsor Xuanwu Hospital, Beijing
Conditions
(from sponsor)		 Alzheimer Disease, Parkinson Disease, Lewy Body Dementia, Multiple System Atrophy, Fronto-temporal Dementia, Amyotrophic Lateral Sclerosis
Related terms Alzheimer Disease, Amyotrophic Lateral Sclerosis, Lewy Body Disease, Multiple System Atrophy, Parkinson Disease
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov